Felbamate — Veterinary Vademecum Drug Reference

Dosage & Administration Guidelines

Species	Route	Dose	Frequency	Duration & Clinical Notes
Dog	PO	Initial: 15 mg/kg q8h; titrate by 10-20 mg/kg/day every 1-2 weeks; maintenance: 30-70 mg/kg/day divided q8h	q8h (every 8 hours)	Duration: Chronic, as needed for seizure control Notes: Therapeutic drug monitoring recommended; target trough levels 20-100 µg/mL. Dose adjustments should be based on clinical response and serum concentrations.
Cat	PO	Not well established; starting dose 15 mg/kg q8h, titrate cautiously	q8h	Duration: Chronic, as needed Notes: Limited data; use with caution and monitor for adverse effects.

Clinical Indications & Species Uses

General Indications

Anticonvulsant for seizure management, primarily in dogs

Dog (Canine)

Adjunctive therapy for refractory epilepsy (partial and generalized seizures)
Treatment of idiopathic epilepsy when other anticonvulsants are ineffective or not tolerated

Pharmacology & Mechanism of Action

Drug Class: Anticonvulsant | Pharmacological Group: Carbamate derivative

Mechanism of Action: Felbamate is a dicarbamate anticonvulsant whose exact mechanism is not fully understood. It is believed to modulate excitatory and inhibitory neurotransmission in the central nervous system. It acts as a low-affinity antagonist at the glycine site of the NMDA receptor, thereby reducing excitatory glutamatergic transmission. Additionally, it potentiates GABA-A receptor-mediated inhibitory transmission, possibly by enhancing GABA release or directly modulating the receptor complex. It also blocks voltage-gated sodium channels and inhibits voltage-gated calcium channels, contributing to its anticonvulsant and neuroprotective effects.

Pharmacodynamics: Felbamate elevates the seizure threshold and reduces the spread of seizure activity. It has a broad-spectrum anticonvulsant profile, effective against partial and generalized seizures. It also exhibits neuroprotective properties in models of hypoxia and ischemia. In veterinary patients, it is used primarily as an adjunctive or alternative therapy for refractory epilepsy. Its effects are dose-dependent, and therapeutic drug monitoring is recommended to maintain plasma concentrations within the target range (typically 20-100 µg/mL in dogs).

⚡ Pharmacokinetics Summary

Absorption: Felbamate is well absorbed after oral administration in dogs and humans. Peak plasma concentrations occur approximately 1-4 hours after dosing. Food does not significantly affect absorption, but may reduce the rate.

Distribution: Felbamate is widely distributed throughout the body. It crosses the blood-brain barrier and achieves cerebrospinal fluid concentrations approximately 30-50% of plasma levels. The volume of distribution is approximately 0.7-1 L/kg in dogs. It is approximately 20-25% bound to plasma proteins.

Metabolism: Felbamate is extensively metabolized in the liver, primarily by cytochrome P450 enzymes (CYP3A4 and CYP2E1 in humans). Major metabolic pathways include hydroxylation and conjugation. It can also undergo hydrolysis to inactive metabolites. In dogs, metabolism is similar, with multiple metabolites identified.

Excretion: Felbamate is excreted primarily in the urine, both as unchanged drug and as metabolites. Approximately 40-50% of the dose is excreted unchanged in the urine in humans. In dogs, renal excretion is also significant. Biliary excretion is minor.

Half-Life: Dogs: 5-8 hours; Cats: not well established, but likely similar or slightly longer; Humans: 20-23 hours.

Bioavailability: Oral bioavailability is approximately 80-90% in dogs and humans.

Protein Binding: 20-25%

Available Formulations & Strengths

Oral Tablet 400 mg, 600 mg (PO)

Oral Suspension 600 mg/5 mL (PO)

Contraindications & Clinical Warnings

Contraindications:

Hypersensitivity to felbamate or any component of the formulation
History of blood dyscrasias (e.g., aplastic anemia) or hepatic dysfunction
Concurrent use with other drugs that may cause hepatotoxicity or bone marrow suppression

Warnings & Clinical Precautions:

Felbamate has been associated with aplastic anemia and hepatotoxicity in humans; although rare in veterinary patients, monitor for signs of bone marrow suppression and liver disease.
Use with caution in patients with renal or hepatic impairment; dose adjustment may be necessary.
Abrupt discontinuation may precipitate withdrawal seizures; taper gradually.
May cause sedation, ataxia, and gastrointestinal upset; monitor during dose titration.
Safety in pregnant or lactating animals has not been established; use only when clearly needed.
In cats, use with extreme caution due to limited safety data.

Adverse Effects & Reactions

Common:

Sedation
Ataxia
Vomiting
Anorexia
Diarrhea
Weight loss

Serious / Severe:

Hepatotoxicity
Aplastic anemia (rare in animals)
Thrombocytopenia
Leukopenia
Severe skin reactions (e.g., Stevens-Johnson syndrome)

Rare:

Renal toxicity
Cardiac arrhythmias
Pancreatitis

Key Drug Interactions

Interacting Drug / Class	Clinical Effect & Mechanism	Severity
Phenobarbital	Felbamate increases phenobarbital concentrations; phenobarbital may decrease felbamate concentrations. Monitor levels and adjust doses.	High
Phenytoin	Felbamate increases phenytoin concentrations; phenytoin may decrease felbamate concentrations. Monitor levels.	High
Valproic acid	Felbamate may increase valproic acid concentrations; valproic acid may decrease felbamate concentrations. Monitor for toxicity.	Moderate
Carbamazepine	Felbamate may increase carbamazepine concentrations and decrease carbamazepine epoxide levels; carbamazepine may decrease felbamate levels.	Moderate
Cimetidine	Cimetidine may increase felbamate concentrations by inhibiting its metabolism.	Moderate
Gabapentin	No significant interaction reported, but additive sedation may occur.	Mild

Overdose & Toxicity Management

Signs of Toxicity:

Ataxia
Sedation
Nausea
Vomiting
Tachycardia
Hypotension
Seizures (paradoxical)
Coma

Emergency Treatment Protocol: Treatment is symptomatic and supportive. Induce emesis if recent ingestion and patient is conscious. Administer activated charcoal to reduce absorption. Provide intravenous fluids, monitor vital signs, and manage seizures with benzodiazepines if necessary. In severe cases, consider hemodialysis (felbamate is dialyzable).

Food Animal Withdrawal Times

Not approved for use in food animals; no withdrawal times established. Use in food animals is prohibited.

Storage, Handling & Regulatory Information

Storage Temperature: Store at controlled room temperature 20-25°C (68-77°F)

Handling & Special Conditions: Keep in a tightly closed container, protect from moisture.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Not FDA-approved for veterinary use; approved for human use (Tablets and Suspension).

Extra-Label (Off-Label) Use: In the US, felbamate is not FDA-approved for veterinary use; its use in animals is extra-label. Under AMDUCA, extra-label use is permitted in non-food animals by or on the order of a veterinarian within a valid VCPR. Use in food animals is prohibited.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Felbamate is a valuable anticonvulsant for dogs with refractory epilepsy, especially when other drugs fail. It is often used as an add-on therapy. Due to the risk of serious adverse effects (aplastic anemia and hepatotoxicity) in humans, careful monitoring is essential. In dogs, adverse effects are generally less severe, but periodic blood work (CBC, liver enzymes) is recommended. Therapeutic drug monitoring is advised to optimize dosing and minimize toxicity. The drug should be tapered gradually to avoid withdrawal seizures. Because of the lack of safety data in cats and other species, its use should be reserved for cases where alternatives are ineffective. Always consider potential drug interactions, especially with other anticonvulsants.

References & Literature

📚 Plumb's Veterinary Drug Handbook
📚 Papich Veterinary Pharmacology and Therapeutics
📚 Compendium of Veterinary Products (CVP)